Research applications · Antibody therapeutics
Tissue & biomarker data for ADC and bispecific research
Explore target expression in clinically characterized tissue for antibody-drug conjugate (ADC) and bispecific T-cell engager programs. Access existing biomarker datasets or add IHC and pathology support to selected TMAs and FFPE cohorts.
Tissue selection for antibody research
Build your study around target expression
ADC target expression
Compare prevalence and expression levels
Explore expression across tumor types and subtypes, including staining intensity, proportion of positive cells and tissue distribution.
Bispecific research
Assess tumor targets and immune context
Select tissue to examine tumor-associated targets alongside immune markers. Add the assays and pathology review appropriate to your research question.
Tumor & normal tissue
Compare expression across tissue types
Use multi-tumor tissue microarrays and normal tissue microarrays to investigate where your target is expressed, then focus on a defined indication or cohort.
Existing IHC datasets
Compare ADC-related targets in breast and lung cancer
IHC assays run on serial TMA sections connect target-level scores and images with available standard-of-care outcomes. The existing work includes hormone receptor-positive and triple-negative breast cancer, and lung adenocarcinoma and squamous cell carcinoma.
Markers evaluated in existing studies
Compare expression across the evaluated targets and explore its relationship to the accompanying clinical record.
- Scored expression
- Pathology review & image-analysis outputs
- Whole-slide images
- H&E and IHC-stained sections
- Clinical context
- Available standard-of-care outcomes
Marker coverage, images and clinical fields are dataset-specific. Serial-section comparisons do not establish same-cell co-localization.
Enquire about these datasetsAuthor affiliations
Seoul National University College of Medicine
TriStar Technology Group
Organizations are identified from author affiliations, patent records and report credits. Their inclusion does not imply a partnership with or endorsement of TriStar.
Selected arrays
TMAs for target-expression studies
Survey tumor and non-malignant tissues, compare treatment groups or select an array with existing molecular characterization. These are tissue options for study planning; they do not all include the ADC-marker dataset described above.
MULTI-TUMOR EXPRESSION SURVEY · TA4340
Multi tumor array comprising breast, bladder(uc), ovarian, lung, prostate, melanoma, RCC , head & neck SCC, CRC, pancreatic adenocarcinoma with histopath data (TA4340)
- Approx. cores
- 120
- Approx. donors
- 120
- Core diameter
- 1mm
NORMAL / NON-MALIGNANT TISSUE · TA3153
RNAscope pre-qualified Normal (non-malignant) samples, 1mm core diameter, ~32 tissue types, 3 donors each (TA3153)
- Approx. cores
- 105
- Approx. donors
- 105
- Core diameter
- 1mm
NSCLC · DONOR-MATCHED PRE/POST · TA3111
NSCLC donor matched pre & post treatment samples with follow up data (TA3111)
- Approx. cores
- 28
- Approx. donors
- 14
- Core diameter
- 1mm
NSCLC · MOLECULAR CHARACTERIZATION · TA4327
NSCLC (adenocarcinoma & squamous cell carcinoma) with histopath data, PD-L1(22C3) status & Oncomine Precision Assay NGS data - optional follow up data (TA4327)
- Approx. cores
- 106
- Approx. donors
- 106
- Core diameter
- 1mm
Counts are approximate. Product details and datasheets describe tissue composition, available data and assay suitability.
Browse all TMAsStudy planning
Different tissue questions for ADCs and bispecifics
Select the tissue and readouts around the therapeutic mechanism being investigated, while keeping expression characterization distinct from functional testing.
ADC target characterization
Compare tumor-antigen expression across indications, molecularly defined subgroups and nonmalignant tissues. IHC can help describe staining intensity, the proportion of positive cells and distribution within the selected tissue. Discuss whole sections when heterogeneity is central to the question, and specify the scoring and image outputs needed.
Bispecific T-cell engager context
Evaluate the tumor target alongside T-cell markers and the surrounding immune context. Define whether you need comparisons across cases, tissue regions or cellular neighborhoods. Serial sections support comparisons between nearby sections; a same-cell or spatial co-localization question requires an appropriate assay and analysis plan.
Interpret the available evidence
Linked standard-of-care treatment and follow-up records provide clinical context; they are not evidence of response to an investigational ADC or bispecific. FFPE expression studies do not establish target internalization, payload activity, T-cell killing or clinical safety. These questions require separate functional or clinical evidence beyond the tissue characterization described here.
Explore target-expression prevalence studies for cohort design and immuno-oncology research for immune-cell and treatment context.
Assays & pathology support
Add assays around your study question
Select protein, RNA or multiplex measurements to complement your tissue cohort and available donor data.
Protein expression
IHC assay services
Characterize antibody targets with established IHC assays or assay development, with pathology scoring defined around your study.
Explore IHC servicesSpatial RNA expression
RNAscope RNA-ISH
Localize target RNA in FFPE tissue, with pre-qualified samples, assay controls and pathologist scoring.
Explore RNAscopeMultiplex protein imaging
Multiplex immunofluorescence
Investigate target co-expression and the relationship between tumor and immune cells with multiplex immunofluorescence on selected tissue.
Work with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.
Our approach begins with our customers’ science.
We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.
Plan your study
Discuss your ADC or bispecific study
Share your targets, tumor indications and required clinical context. We’ll review existing datasets, suitable tissue and any staining, scoring or image analysis you would like to add.